GLS.NS

Glenmark Life Sciences Limited [GLS.NS] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

GLS.NS Stock Summary

In the News

GLS.NS Financial details

Company Rating
-
Market Cap
99.11B
Income
5.19B
Revenue
23.68B
Book val./share
-
Cash/share
-
Dividend
43.5
Dividend %
5.84%
Employees
1.82K
Optionable
No
Shortable
Yes
Earnings
18 Apr 2024
P/E
18.06
Forward P/E
-
PEG
9.55
P/S
3.91
P/B
3.82
P/C
-
P/FCF
2866.98
Quick Ratio
2.65
Current Ratio
4.16
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
42.37
EPS next Y
-
EPS next Q
-
EPS this Y
6.96%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
9.79%
Revenue last 5Y
8.99%
Revenue Q/Q
-3.79%
EPS Q/Q
-
-
-
-
-
SMA20
5.3%
SMA50
5.14%
SMA100
-
Inst Own
-
Inst Trans
-
ROA
17%
ROE
45%
ROC
0.28%
Gross Margin
54%
Oper. Margin
29%
Profit Margin
22%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
411.05-906.0
52W High
+16.79%
52W Low
+157.45%
RSI
43.01
Rel Volume
0.67
Avg Volume
161.77K
Volume
108.45K
Perf Week
-14.47%
Perf Month
1.4%
Perf Quarter
-
Perf Half Y
8.07%
-
-
-
-
Beta
0.123
-
-
Volatility
80.3%, 75.3%
Prev Close
4.42%
Price
1058.1
Change
2.73%

GLS.NS Financial Performance

GLS.NS Dividend History

GLS.NS Frequently Asked Questions

What is Glenmark Life Sciences Limited stock symbol ?

Glenmark Life Sciences Limited is a IN stock and trading under the symbol GLS.NS

What is Glenmark Life Sciences Limited stock quote today ?

Glenmark Life Sciences Limited stock price is $1058.1 today.

Is Glenmark Life Sciences Limited stock public?

Yes, Glenmark Life Sciences Limited is a publicly traded company.

Something similar

Top by Market Cap
ABEC.DE
LLY.SW
META
CMC.DE
AAPL
Same Sector
GIKLY
0JBU.L
300573.SZ
6491.TW
LUPIN.NS
Check Those
EDOG
EKGAX
2882.HK
VISN
EVSBY
Similar Market Cap
3487.T
015230.KS
350520.KS
0OAL.L
004415.KS

Company Profile

Healthcare Drug Manufacturers - Specialty & Generic
  • Volume Average 161.77K
  • Market Capitalization 99.11B
  • Employee 1.82K
  • CEO Dr. Yasir Yusufali Rawjee Ph.D.
  • Headquarters Mumbai,IN
  • IPO Date 2021-08-06
  • Website https://www.glenmarklifesciences.com

Glenmark Life Sciences Limited develops, manufactures, and supplies non-commoditized active pharmaceutical ingredients for various chronic therapeutic areas in India. The company offers Olmesartan, Amiodarone, Telmisartan, Perindopril, Rosuvastatin, and Cilostazol for cardiovascular diseases; Oxcarbazepine, Zonisamide, Topiramate, Bupropion, Ropinirole, Riluzole, and Lacosamide for central nervous system diseases; Glimepiride, Teneligliptin, Vildagliptin, and Linagliptin for diabetes; and Etoricoxib and Lornoxicam for pain management. It also provides Atovaquone, Voriconazole, Mirabegron, Desloratadine, Esomeprazole Magnesium, Adapalene, and Fluconazole gastro-intestinal disorders, anti-infective, respiratory, anti-emetic, and other therapeutic areas. In addition, the company offers contract development and manufacturing services to a range of multinational pharmaceutical and specialty pharmaceutical companies. It also exports its products to Europe, North America, Latin America, Japan, and internationally. The company was incorporated in 2011 and is based in Mumbai, India. Glenmark Life Sciences Limited is a subsidiary of Glenmark Pharmaceuticals Limited.